There are 195 Gene Therapy investors in the AngelBacked database, ranked below by portfolio size. The most active include David Bonita, Carter Neild and Carl Gordon. Each profile lists portfolio companies, sector focus, check size, and contact details.
Chief Financial Officer and Partner
Senior Associate, Business Development
Senior Associate, Business Development
Vice President, Sandbox Healthcare
Chief Operating Officer and Chief Financial Officer
Sign up to view contact details, LinkedIn profiles, and export investor data.
AngelBacked lists 195 angel investors and VCs who invest in Gene Therapy startups. The most active by portfolio size include David Bonita, Carter Neild, Carl Gordon.
Ranked by number of portfolio companies, the most active Gene Therapy investors in the AngelBacked database are David Bonita, Carter Neild, Carl Gordon. Each profile lists their portfolio, sector focus, and contact details.
Every Gene Therapy investor profile on AngelBacked includes a verified email address alongside their portfolio companies, sector focus, and firm. Paid plans unlock the contact details and CSV export.
Check sizes vary by stage: angel investors backing Gene Therapy startups typically write $25K–$100K, while Gene Therapy-focused VCs range from $500K to $5M+ for early-stage rounds. Filter the database by check size to match your raise.